This is not only good news for all prostate cancer patients, but is also good news for all cancer patients.
The investigational radiopharmaceutical radium-223 chloride (Alpharadin) has recently been shown to improve survival in patients with advanced prostate cancer and bone metastases. This agent could potentially be used in other cancer patients to extend their lives.
The beauty of this product is that it is highly targeted for bone metastases; so this product will be valuable for many different Stage IV cancers patients whose cancers have spread to bones.
Radium-223 chloride works by releasing minute, highly charged, targeted doses of radiation (alpha particles) that are highly lethal to cancer cancers but have a short penetration. This specific targeting delivers radiation to the bone metastases and minimizes the damage done elsewhere.
Filed under: Anal Cancer, Bladder Cancer, Breast cancer, Cancer, Colon cancer, Endometrial Cancer, Esophageal Cancer, Gallbladder cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma, Nasopharyngeal Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate cancer, Renal Cancer, Small Cell Lung Cancer, Thyroid Cancer | Tagged: abiraterone, advanced prostate cancer, Alpharadin, ALSYMPCA, bone metastases, Cancer, carbitaxel, docetaxel, immunotherapy, Jevtana, Prostate cancer, Provenge, radium-223 chloride, sipuleucel-T, Stage IV cancers, Survival, Taxotere, Zytiga | Leave a comment »
Healthreason.com 